Before you place any bets on NFL Sunday, you'll want to check out the latest DraftKings promo code offering $300 in bonus bets and three months of free NBA League Pass. The Week 9 NFL schedule ...

Start the week with BetMGM promo code NOLA150 and lock in bonuses for Monday Night Football, ALCS Game 7 or any other matchup. New users will have no shortage of options with the NFL, MLB, NBA and NHL ...

Score a bonus for NCAAF and NFL picks by signing up with the Underdog promo code NEWSWEEK. New customers can activate this welcome offer for a weekend full of football by clicking here. Create your ...

AJ Styles' promo during a commercial break on this week's WWE RAW has generated a significant amount of buzz in the wrestling world. When done right, promos that blur the lines between reality and ...

NFL Sunday is here and the latest DraftKings promo code offers $300 in bonus bets instantly and over $200 off NFL Sunday Ticket so you don't have to miss a second of the action. Whether you're trying ...

Breast cancer maintains its position as the most prevalent malignancy in women worldwide, with triple-negative breast cancer (TNBC) representing the most treatment-resistant subtype due to limited ...

Karrion Kross is gone from WWE, with the former WWE NXT Champion's contract expiring recently. Kross's exit was met with much speculation, as many wondered if Kross was involved in some kind of angle, ...

It may come as no surprise that breast cancer is the most common cancer in women worldwide. In the United States, about 275,000 women are diagnosed with breast cancer each year. Triple-negative breast ...

Triple-negative breast cancer (TNBC) was first described as a distinct disease entity 20 years ago. Since that time, there has been tremendous effort invested in understanding the clinical features ...

Sacituzumab govitecan combined with pembrolizumab improved progression-free survival in PD-L1–positive metastatic triple-negative breast cancer compared with chemotherapy. Vepdegestrant, a PROTAC ...

Proteinqure Inc. has closed an $11 million series A financing round to support the initiation of the company’s first clinical trial for PQ-203, a first-in-class peptide-drug conjugate for ...